SI1569679T1 - Imunosupresija s šaperoninom 10 - Google Patents

Imunosupresija s šaperoninom 10

Info

Publication number
SI1569679T1
SI1569679T1 SI200331912T SI200331912T SI1569679T1 SI 1569679 T1 SI1569679 T1 SI 1569679T1 SI 200331912 T SI200331912 T SI 200331912T SI 200331912 T SI200331912 T SI 200331912T SI 1569679 T1 SI1569679 T1 SI 1569679T1
Authority
SI
Slovenia
Prior art keywords
donor
recipient animal
cpn10
administration
host disease
Prior art date
Application number
SI200331912T
Other languages
English (en)
Inventor
Geoffrey R Hill
Tatjana Banovic
Halle Morton
Alice Christina Cavanagh
Original Assignee
Cbio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cbio Ltd filed Critical Cbio Ltd
Publication of SI1569679T1 publication Critical patent/SI1569679T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Glass Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SI200331912T 2002-11-06 2003-11-06 Imunosupresija s šaperoninom 10 SI1569679T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2002952492A AU2002952492A0 (en) 2002-11-06 2002-11-06 Chaperonin 10 immunosuppression
PCT/AU2003/001467 WO2004041300A1 (en) 2002-11-06 2003-11-06 Chaperonin 10 immunosuppression
EP03769073A EP1569679B1 (en) 2002-11-06 2003-11-06 Chaperonin 10 immunosuppression

Publications (1)

Publication Number Publication Date
SI1569679T1 true SI1569679T1 (sl) 2011-01-31

Family

ID=28795882

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200331912T SI1569679T1 (sl) 2002-11-06 2003-11-06 Imunosupresija s šaperoninom 10

Country Status (16)

Country Link
US (3) US7618935B2 (sl)
EP (3) EP2818179A1 (sl)
JP (2) JP4716731B2 (sl)
KR (1) KR101088740B1 (sl)
CN (1) CN100525832C (sl)
AT (1) ATE489963T1 (sl)
AU (1) AU2002952492A0 (sl)
CA (1) CA2505141C (sl)
CY (1) CY1110972T1 (sl)
DE (1) DE60335202D1 (sl)
DK (1) DK1569679T3 (sl)
ES (1) ES2351993T3 (sl)
NZ (1) NZ540433A (sl)
PT (1) PT1569679E (sl)
SI (1) SI1569679T1 (sl)
WO (1) WO2004041300A1 (sl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005204979B2 (en) * 2004-01-16 2010-10-21 Cbio Limited Chaperonin 10 modulation of toll-like receptor-inducible cytokine and chemokine secretion
NZ548985A (en) * 2004-01-16 2010-02-26 Cbio Ltd Chaperonin 10 modulation of toll-like receptor-inducible cytokine and chemokine secretion
US8036710B2 (en) * 2004-05-07 2011-10-11 Qualcomm, Incorporated Power-efficient multi-antenna wireless device
AU2006269824B2 (en) * 2005-07-11 2012-04-19 Cbio Limited Chaperonin 10-induced immunomodulation
MX2008000596A (es) * 2005-07-11 2008-03-19 Cbio Ltd Inmunomodulacion inducida por la chaperonina 10.
NZ566817A (en) * 2005-08-31 2012-02-24 Cbio Ltd Modified chaperonin 10, wherein the N-terminus comprises a single additional glycine residue compared to a corresponding mammalian wild-type
EP1951282A4 (en) * 2005-10-20 2009-09-02 Cbio Ltd TREATMENT OF HYPERSENSITIVITY
AU2006303826B2 (en) * 2005-10-20 2012-07-19 Cbio Limited Treatment of hypersensitivity
CA2644058C (en) 2006-03-02 2016-08-09 Cbio Limited Regulation of immune responses by modulation of the function of antigen presenting cells
WO2009124353A1 (en) * 2008-04-11 2009-10-15 Cbio Limited Modified cpn10 and prr signalling
US20110243921A1 (en) * 2010-03-30 2011-10-06 Cbio Limited Prevention and treatment of cutaneous lupus erythematosus
WO2013158959A1 (en) * 2012-04-19 2013-10-24 Tarix Pharmaceuticals Ltd. Compositions and methods for treatment of graft-versus-host disease
US9688741B2 (en) 2012-10-23 2017-06-27 Elastagen Pty Ltd Elastic hydrogel
RU2668877C2 (ru) 2012-12-10 2018-10-04 Эластаджен Пти Лтд, Масштабируемое получение трехмерных эластичных конструкций
JP6382311B2 (ja) 2013-08-13 2018-08-29 エラスタジェン・プロプライエタリー・リミテッドＥｌａｓｔａｇｅｎ Ｐｔｙ Ｌｔｄ 損傷組織の再生

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2176948C (en) * 1993-11-30 2007-05-15 Halle Morton Chaperonin 10
PT731811E (pt) * 1993-11-30 2005-04-29 Univ Queensland Chaperonina 10
US5989804A (en) * 1994-07-08 1999-11-23 New England Medical Center Hospitals, Inc. E6 binding proteins
JPH11510806A (ja) * 1995-08-09 1999-09-21 シェーリング コーポレイション 免疫抑制治療のためのインターロイキン１０およびシクロスポリンの併用
US20020142000A1 (en) * 1999-01-15 2002-10-03 Digan Mary Ellen Anti-CD3 immunotoxins and therapeutic uses therefor
EP1218030A4 (en) * 1999-09-10 2004-09-15 Univ Fordham METHODS AND COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF GRAFT REJECTS USING THERMAL SHOCK PROTEINS
GB0028122D0 (en) * 2000-11-17 2001-01-03 St Georges Entpr Ltd Method

Also Published As

Publication number Publication date
US8067361B2 (en) 2011-11-29
DE60335202D1 (en) 2011-01-13
CA2505141A1 (en) 2004-05-21
CN100525832C (zh) 2009-08-12
EP2818179A1 (en) 2014-12-31
AU2002952492A0 (en) 2002-11-21
EP1569679B1 (en) 2010-12-01
EP2255824B1 (en) 2014-07-23
US20100099605A1 (en) 2010-04-22
NZ540433A (en) 2008-03-28
PT1569679E (pt) 2010-12-14
EP1569679A4 (en) 2008-02-27
US7618935B2 (en) 2009-11-17
CN1735428A (zh) 2006-02-15
JP2006508099A (ja) 2006-03-09
CA2505141C (en) 2012-07-17
WO2004041300A1 (en) 2004-05-21
JP4716731B2 (ja) 2011-07-06
KR20050086428A (ko) 2005-08-30
EP2255824A1 (en) 2010-12-01
ATE489963T1 (de) 2010-12-15
KR101088740B1 (ko) 2011-12-01
JP2011088920A (ja) 2011-05-06
EP1569679A1 (en) 2005-09-07
US20120082690A1 (en) 2012-04-05
ES2351993T3 (es) 2011-02-14
DK1569679T3 (da) 2011-01-10
CY1110972T1 (el) 2015-06-11
US20060198834A1 (en) 2006-09-07

Similar Documents

Publication Publication Date Title
CY1110972T1 (el) Ανοσοκαταστολη με σαπερονινη 10
HK1071313A1 (en) Preventing and/or treating cardiovascular disease and/or associated heart failure
PT2163614T (pt) Animais porcinos que carecem de qualquer expressão de alfa 1,3 galactosiltransferase funcional
EP1688425A3 (en) Cyclic salen-metal compounds as scavengers for oxygen radicals and useful as antioxidants in the treatment and prevention of diseases
HK1087042A1 (en) New use of dextran sulfate
ES2114888T3 (es) Tratamiento contra el rechazo en el transplante de organos.
EP1676574A3 (en) Methods for promoting survival of transplanted tissues and cells
SI1546088T1 (sl) Spojine za uporabo v zdravljenju avtoimunskih bolezni, imunoalergijskih bolezni in zavrnitve transpalantata organa ali tkiva
HK1023599A1 (en) Cells for preventing graft rejection in transplantation and their uses.
HU901516D0 (en) The use of s-adenosile-methionine in the treatment of pancreatitis, and in preventing the natural rejection of transplanted pancreas
WO2003102162A3 (en) Novel tolerogenic dendritic cells and therapeutic uses therefor
DE3875306D1 (de) Immunosuppression bei der auf immunotoxin basierten behandlung von menschen.
HK1060855A1 (en) Use of accelerated lymphocyte homing agents for the manufacture of a medicament for the treatment ofdelayed graft function
WO2005041877A3 (en) Method of inhibiting rejection following organ transplantation
EP1964572A3 (en) Compositions and methods for protecting organs, tissue and cells from immune system-mediated damage
EP0929217A4 (en) SORDARIN DERIVATIVES
MXPA05004121A (es) Metodos para tratar la enfermedad de ojo reseco con lantibioticos.
DE60023034D1 (en) Cd45 hemmer
BG104259A (en) Derivatives of 4-cyano-4-deformylsordaricin
PL338704A1 (en) Derivatives of 4-cyano-4-deformylsordarin
HUP0103107A2 (hu) Allogénikus és xenogénikus T-sejtek ex vivo kezelése gp39 antagonistákkal
of Man An act (Chapter No. 3) to prohibit commercial dealings in human organs intended for transplanting; to prohibit the transplanting of such organs between persons who are not genetically related; and for connected purposes. Dated 16 March 1993.(The Human Organ Transplants Act 1993)
Begley et al. World's First Mechanical Heart Implanted
CA2254889A1 (en) A promoter gene for a porcine complement inhibitor
ATE283063T1 (de) Allogene und xenogene transplantation